Status
Conditions
Treatments
About
The study hypothesizes that donepezil will have a positive impact on brain blood flow deficits in subjects with memory deficits and/or mild dementia and that improvements in brain blood flow will be accompanied by improvements in memory.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Type II diabetic subjects may be included provided that their disease and serum glucose values are controlled and being actively managed, as assessed by the PI using a fasting blood sugar and/or HgbA1C (per the PI's medical judgment in consultation with the Sponsor).
Exclusion criteria
Exclusions Related to Medications or Procedures
Use of medication(s) for cognitive enhancement ≤ 90 days before the first dose of study medication.
Prescription: including but not limited to donepezil, galantamine, rivastigmine, tacrine, memantine, Axona™;
Reason for stoppage of donepezil may not be related to tolerability issues or to gain entry in this study.
Non-prescription treatments for cognitive enhancement.
Primary purpose
Allocation
Interventional model
Masking
18 participants in 2 patient groups, including a placebo group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal